

Vijaya's Q4FY26 results surpassed our/street estimates. Revenue/EBITDA grew 27%/39% YoY, respectively, supported by volume growth (+18% YoY) and operating leverage. Vijaya's dense network, clinician talent, high-end equipment, and strong brand equity have led to continued market-share gains in Hyderabad, reinforcing its leadership position in its mature/core cluster. With new clusters now stabilized (Pune reported 16% YoY growth in Q4) and network expansion continuing in FY27, we expect Vijaya's growth momentum to accelerate, and estimate 19% revenue CAGR over FY26-28. Faster-than-guided breakeven in non-core regions (Khammam and Nandyal hubs saw breakeven within 2 quarters) underpins Vijaya's execution prowess and allays concerns around the scalability of an integrated operator. We anticipate ~150bps EBITDA margin expansion by FY28E on the back of the company's strategy of accelerating spoke additions and higher share from wellness testing. Factoring in the Q4 beat, we raise FY27E/FY28E EBITDA by 4%/3% and Mar-27E TP by ~8% to Rs1,400 from Rs1,300 (DCF methodology). We retain BUY. Elevated growth trajectory, strong net-cash balance sheet, and superior cash-flow generation provide comfort on valuations. CMP implies FY28E PER of 47x – a 15% premium to that of DLPL.

Strong end to the year

For Q4FY26, consolidated revenue grew 27% YoY to Rs2.2bn (+5%/6% vs street/our estimate), with overall patient/sample volumes growing 15%/18% YoY. The Wellness segment accounted for 15.6% of the topline (+32% YoY). Revenue growth was broad-based across clusters, with new units in non-core geographies (RoAPT) achieving breakeven within two quarters of commissioning. Gross margin expanded by 143bps YoY while EBITDA margin, largely backed by operational leverage, expanded by 379bps to 43.5%. Adj PAT grew 34% YoY to Rs479mn. Net cash balance stands at Rs2.8bn as of Mar-26. The company has declared a dividend of Rs2/share. OCF/EBITDA conversion continues to be robust, at 80% in FY26.

Outlook and risks

Vijaya's growth engine continues to deliver volume-led growth across clusters. The accelerating revenue growth momentum (+20% YoY), even in its mature geography (Hyderabad), highlights the company's strong brand equity and sustainable business moats as it continues to gain market share. We remain constructive on Vijaya's capabilities to replicate its set template of delivering profitable growth, even in non-core geographies, on the back of achieving faster-than-anticipated breakeven in newly commissioned hubs in RoAPT market. With plans to add 10-12 spokes and 4-5 hubs in FY27, Vijaya's network densification strategy should further accelerate the growth trajectory, in our view. A strong balance sheet (net cash: Rs2.8bn as of Mar-26) and superior cash-flow generation (OCF as a % of EBITDA at 80% in FY26) lend comfort on valuations (CMP implies FY28E PER of 47x and EV/OCF of 32x). Key risks: Increased competition in the organized market (non-core markets) and any adverse regulatory rulings on pricing for healthcare services.

Target Price – 12M	Mar-27
Change in TP (%)	7.7
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	9.5

Stock Data	VIJAYA IN
52-week High (Rs)	1,300
52-week Low (Rs)	848
Shares outstanding (mn)	102.9
Market-cap (Rs bn)	132
Market-cap (USD mn)	1,393
Net-debt, FY27E (Rs mn)	(4,459.6)
ADTV-3M (mn shares)	0.2
ADTV-3M (Rs mn)	149.9
ADTV-3M (USD mn)	1.6
Free float (%)	46.9
Nifty-50	24,176.2
INR/USD	94.5


Shareholding, Mar-26

Promoters (%)	52.5
FPIs/MFs (%)	13.4/29.9

Price Performance

(%)	1M	3M	12M
Absolute	32.8	32.5	27.9
Rel. to Nifty	31.8	40.8	28.4

1-Year share price trend (Rs)



Vijaya Diagnostic: Financial Snapshot (Consolidated)

Y/E March (Rs mn)	FY24	FY25	FY26	FY27E	FY28E
Revenue	5,478	6,814	8,142	9,670	11,464
EBITDA	2,209	2,732	3,369	4,112	4,901
Adj. PAT	1,209	1,441	1,730	2,163	2,792
Adj. EPS (Rs)	11.8	14.0	16.8	21.0	27.1
EBITDA margin (%)	40.3	40.1	41.4	42.5	42.8
EBITDA growth (%)	21.4	23.7	23.3	22.0	19.2
Adj. EPS growth (%)	43.0	18.9	19.7	25.0	29.1
RoE (%)	20.1	19.8	19.7	20.4	21.5
RoIC (%)	40.2	36.7	37.8	39.8	47.6
P/E (x)	110.2	91.1	76.1	60.8	47.1
EV/EBITDA (x)	58.4	47.2	38.3	31.4	26.3
P/B (x)	19.9	16.5	13.7	11.3	9.2
FCFF yield (%)	(0.4)	0.4	1.1	1.4	2.2

Source: Company, Emkay Research

Anshul Agrawal


anshul.agrawal@emkayglobal.com
+91-22-66121228

Vivek Sethia

vivek.sethia@emkayglobal.com
+91-22-66121306


Story in charts

Exhibit 1: Sample/patient volumes grew 18%/15% in Q4




Source: Company, Emkay Research

Exhibit 2: Revenue grew 27% YoY in Q4, led by volumes




Source: Company, Emkay Research

Exhibit 3: Sample/patient realizations increased 7%/9% YoY




Source: Company, Emkay Research

Exhibit 4: EBITDAM expanded by 379bps YoY, while PATM expanded by 185bps (attributable to higher depreciation)




Source: Company, Emkay Research

Exhibit 5: Radiology mix was stable at 37% in Q4FY26



Source: Company, Emkay Research

Exhibit 6: We anticipate return ratios to improve over FY26-28E



Source: Company, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)

Exhibit 7: Summary of quarterly financials

Particulars (Rs mn)	Q4FY25	Q3FY26	Q4FY26	YoY chg	QoQ chg	FY25	FY26	YoY chg
Net sales	1,732	2,052	2,194	27%	7%	6,814	8,142	19%
Operating expenses	1,044	1,192	1,239	19%	4%	4,082	4,773	17%
Medical consumable costs	222	240	249	12%	4%	848	947	12%
Employee costs	284	330	338	19%	2%	1,122	1,307	17%
SG&A expenses	538	621	651	21%	5%	2,113	2,518	19%
EBITDA	689	861	955	39%	11%	2,732	3,369	23%
- Margin	39.8%	41.9%	43.5%			40.1%	41.4%	
Depreciation	(188)	(243)	(243)	29%	0%	(706)	(918)	30%
EBIT	500	617	712	42%	15%	2,026	2,451	21%
Other income	55	51	24	-57%	-53%	183	208	14%
Interest	(72)	(86)	(93)	30%	8%	(267)	(332)	24%
Extraordinary items	10	0	0			10	0	
PBT	474	582	643	36%	10%	1,932	2,327	20%
Tax	(125)	(150)	(163)	31%	9%	(494)	(597)	21%
PAT	349	432	479	37%	11%	1,438	1,730	20%
Adj PAT	359	432	479	34%	11%	1,448	1,730	19%
Minority interest	2	0	0			7	3	
PAT (reported)	346	432	479	38%	11%	1,431	1,727	21%
Adj EPS (Rs)	3.50	4.20	4.66	33%	11%	14.11	16.81	19%
(%)	Q4FY25	Q3FY26	Q4FY26	YoY (bps)	QoQ (bps)	FY25	FY26	YoY (bps)
Gross margin	87.2%	88.3%	88.6%	143	34	87.6%	88.4%	81
EBITDAM	39.8%	41.9%	43.5%	379	161	40.1%	41.4%	129
EBITM	28.9%	30.1%	32.5%	357	238	29.7%	30.1%	37
EBTM	27.3%	28.4%	29.3%	195	92	28.3%	28.6%	23
PATM	20.0%	21.0%	21.8%	185	81	21.0%	21.2%	22
Effective tax rate	26.4%	25.8%	25.4%	-98	-42	25.6%	25.7%	10

Source: Company, Emkay Research

Exhibit 8: Actuals vs estimates (Q4FY26)

(Rs mn)	Actual	Estimate	Consensus	Variation	
		(Emkay)	estimate		
			(Bloomberg)	Emkay	Consensus
Revenue	2,194	2,080	2,095	5%	5%
EBITDA	955	863	870	11%	10%
EBITDA margin	44%	42%	42%	204bps	201bps
PAT	479	456	448	5%	7%

Source: Company, Emkay Research

Exhibit 9: Change in estimates

Particulars (Rs mn)	FY27E			FY28E		
	Old	New	Change	Old	New	Change
Revenue	9,543	9,670	1.3%	11,313	11,464	1.3%
EBITDA	3,938	4,112	4.4%	4,779	4,901	2.5%
EBITDA margin	41.3%	42.5%	126 bps	42.2%	42.8%	50 bps
PAT	2,171	2,163	-0.4%	2,849	2,792	-2.0%

Source: Company, Emkay Research


This report is intended for Team White Marque Solutions (team.emkay@whitemarqueresolutions.com)

Exhibit 10: We raise our TP for Vijaya Diagnostic by ~8% to Rs1,400 from Rs1,300

(Rs mn)	FY25	FY26	FY27E	FY28E	FY30E	FY35E
Revenue	6,814	8,142	9,670	11,464	15,561	28,760
- Growth	24%	19%	19%	19%	18%	13%
NOPAT	1,511	1,828	2,271	2,748	3,962	7,428
Non-cash items	706	918	1,043	1,188	1,454	2,688
Change in WC	19	(16)	22	26	30	38
Capex	(956)	(1,827)	(1,475)	(1,045)	(906)	(955)
FCFF	1,281	903	1,861	2,917	4,540	9,199
WACC	11%					
Terminal growth	6%					
PV of CFs (FY28-45E)	65,081					
PV of terminal value	69,289					
Total EV	1,34,370					
(Less) net debt – FY28E	(6,826)					
Total equity value	1,41,197					
Total no of shares (mn)	102					
Target price – Mar-27E (Rs)	1,400					


Source: Company, Emkay Research

Exhibit 11: Vijaya Diagnostic is trading close to its +1SD 1YF PER



Source: Company, Bloomberg, Emkay Research

Exhibit 12: Vijaya Diagnostic trades at a premium to DLPL (1YF PER) on the back of elevated growth outlook



Source: Company, Bloomberg, Emkay Research

Call highlights

Network expansion and geography

- Two new hubs opened in Q3—Khammam and Nandyal—both achieved breakeven in 2 quarters, ahead of the 3-quarter target for Vijaya.
- The company is targeting 12 spokes + 4-5 hubs in FY27, with >40% margin. New center additions bring incremental costs, but the management remains positive to achieve >40% EBITDA margin.
- Four new hub leases have been signed for future expansion; all hubs in the capex plan have executed signed leases.

Capital allocation plans

- The company incurred Rs1.7bn capex in FY26 (including replacement capex). The management guided for a capex of Rs1.4-1.5bn for FY27, covering new hub and spoke additions, automated lab (Rs200mn), and maintenance capex (Rs100-120mn).
- Maintenance capex is guided at 2–2.5% of topline on an ongoing basis.
- The company is open to inorganic opportunities where there is clear value addition. Entry into new clusters via acquisition would depend on the size of the target in the region where it operates.

Margin drivers and operating leverage

- Revenue per test (RPT) is increasing as new hubs ramp up; RPT in the first year of a hub's operations is primarily driven by radiology.
- Margin growth to be driven by focus on volume growth rather than price increases.

City-wise updates

- Kolkata: There are 7 hub centers in total. The VIP Road center showed double-digit YoY growth. Five centers were opened in FY26 – 2 centers achieved breakeven in 3 quarters, while the other 3 achieved within 9 months.
- Pune: Revenue grew 16% YoY in Q4FY26. The company's second hub in Kalyani Nagar opened in Q2FY26 and is expected to take ~1 year to reach breakeven.
- Bengaluru: Yelahanka has reached breakeven; HSR is closer to breakeven. Vijaya is looking to open new centers in Rajajinagar and JP Nagar. The management is optimistic about Bengaluru, as despite a strong pathology competition, Vijaya's integrated model and hub-and-spoke presence in micro-clusters is a key differentiator. Cardiac PET-CT is coming to JP Road flagship hub within the next 2 months. The company is also looking to bring a similar capability center elsewhere in Hyderabad.
- No plans to expand into North India for at least the next 3–5 years.

Technology and digital investments

- The management stated that work on AI has begun in the fag-end of Q4FY26, with discussions underway with external firms to implement AI across multiple modalities. This will be an ongoing process.
- Digital marketing: Rs60–70mn spent in FY26; expected to double in FY27.

Financial overview

- Pre-IndAS margin for Q4/FY26 stood at ~35% for FY26.
- Wellness realizations were at Rs1,800–2,000 in Q4 (closer to Rs2,000 for FY26), with retail realizations slightly higher at over Rs2,500.
- A price hike of 1–1.5% is planned for Q1/Q2FY27, like the Q1FY26 hike. Some churn in corporate clients has been observed due to price sensitivity.
- The wellness segment showed strong growth in Q4, with growth from retail customers in line with overall company growth.

Vijaya Diagnostic: Consolidated Financials and Valuations

Profit & Loss

Y/E March (Rs mn)	FY24	FY25	FY26	FY27E	FY28E
Revenue	5,478	6,814	8,142	9,670	11,464
Revenue growth (%)	19.3	24.4	19.5	18.8	18.6
EBITDA	2,209	2,732	3,369	4,112	4,901
EBITDA growth (%)	21.4	23.7	23.3	22.0	19.2
Depreciation & Amortization	570	706	918	1,043	1,188
EBIT	1,639	2,026	2,451	3,069	3,714
EBIT growth (%)	36.2	23.6	21.0	25.2	21.0
Other operating income	-	-	-	-	-
Other income	208	183	208	322	500
Financial expense	240	267	332	468	490
PBT	1,607	1,942	2,327	2,923	3,723
Extraordinary items	(21)	0	0	0	0
Taxes	390	494	597	760	931
Minority interest	(8)	(7)	0	0	0
Income from JV/Associates	-	-	-	-	-
Reported PAT	1,188	1,441	1,730	2,163	2,792
PAT growth (%)	40.4	21.3	20.0	25.0	29.1
Adjusted PAT	1,209	1,441	1,730	2,163	2,792
Diluted EPS (Rs)	11.8	14.0	16.8	21.0	27.1
Diluted EPS growth (%)	43.0	18.9	19.7	25.0	29.1
DPS (Rs)	1.0	2.0	2.0	1.0	1.0
Dividend payout (%)	8.6	14.2	11.9	4.8	3.7
EBITDA margin (%)	40.3	40.1	41.4	42.5	42.8
EBIT margin (%)	29.9	29.7	30.1	31.7	32.4
Effective tax rate (%)	24.3	25.4	25.7	26.0	25.0
NOPLAT (pre-IndAS)	1,241	1,511	1,822	2,271	2,785
Shares outstanding (mn)	102	103	103	103	103

Source: Company, Emkay Research

Cash flows

Y/E March (Rs mn)	FY24	FY25	FY26	FY27E	FY28E
PBT (ex-other income)	1,399	1,759	2,119	2,601	3,223
Others (non-cash items)	-	-	-	-	-
Taxes paid	(390)	(494)	(597)	(760)	(931)
Change in NWC	10	359	(441)	22	26
Operating cash flow	1,833	2,245	2,706	3,340	3,962
Capital expenditure	(2,298)	(1,702)	(1,337)	(1,509)	(1,079)
Acquisition of business	0	0	0	0	0
Interest & dividend income	60	58	56	0	0
Investing cash flow	(1,423)	(1,819)	(1,742)	(1,179)	(1,346)
Equity raised/(repaid)	-	-	-	0	0
Debt raised/(repaid)	0	0	0	0	0
Payment of lease liabilities	(147)	(243)	(244)	32	(458)
Interest paid	(240)	(267)	(332)	(468)	(490)
Dividend paid (incl tax)	(102)	(205)	(206)	(103)	(103)
Others	(203)	783	534	535	536
Financing cash flow	(692)	68	(248)	(4)	(514)
Net chg in Cash	(282)	494	716	2,157	2,103
OCF	1,833	2,245	2,706	3,340	3,962
Adj. OCF (w/o NWC chg.)	1,823	1,885	3,147	3,318	3,936
FCFF	(465)	543	1,369	1,831	2,884
FCFE	(645)	333	1,093	1,363	2,393
OCF/EBITDA (%)	83.0	82.2	80.3	81.2	80.8
FCFE/PAT (%)	(54.3)	23.1	63.2	63.0	85.7
FCFF/NOPLAT (%)	(37.5)	35.9	75.2	80.7	103.5

Source: Company, Emkay Research

Balance Sheet

Y/E March (Rs mn)	FY24	FY25	FY26	FY27E	FY28E
Share capital	102	103	103	103	103
Reserves & Surplus	6,470	7,855	9,469	11,529	14,218
Net worth	6,572	7,957	9,572	11,632	14,321
Minority interests	27	34	0	0	0
Non-current liab. & prov.	(29)	53	145	145	145
Total debt	0	0	0	0	0
Total liabilities & equity	9,162	11,240	13,942	16,061	19,093
Net tangible fixed assets	3,786	4,469	5,625	6,416	6,687
Net intangible assets	207	219	204	225	244
Net ROU assets	3,188	4,035	5,309	5,336	6,136
Capital WIP	82	703	343	343	343
Goodwill	1,192	1,192	1,192	1,192	1,192
Investments [JV/Associates]	-	-	-	-	-
Cash & equivalents	1,822	2,335	2,811	4,460	6,826
Current Liab. & Prov.	637	1,496	1,128	1,198	1,281
NWC (ex-cash)	(168)	(446)	88	65	39
Total assets	9,162	11,240	13,942	16,061	19,093
Net debt	(1,822)	(2,335)	(2,811)	(4,460)	(6,826)
Capital employed	9,162	11,240	13,943	16,061	19,093
Invested capital	4,070	4,168	5,479	5,922	5,787
BVPS (Rs)	64.2	77.5	93.0	113.0	139.2
Net Debt/Equity (x)	(0.3)	(0.3)	(0.3)	(0.4)	(0.5)
Net Debt/EBITDA (x)	(0.8)	(0.9)	(0.8)	(1.1)	(1.4)
Interest coverage (x)	7.7	8.3	8.0	7.2	8.6
RoCE (%)	30.6	30.3	30.3	32.0	32.5

Source: Company, Emkay Research

Valuations and key Ratios

Y/E March	FY24	FY25	FY26	FY27E	FY28E
P/E (x)	110.2	91.1	76.1	60.8	47.1
EV/CE(x)	19.6	16.2	13.5	11.1	9.0
P/B (x)	19.9	16.5	13.7	11.3	9.2
EV/Sales (x)	23.6	18.9	15.9	13.3	11.3
EV/EBITDA (x)	58.4	47.2	38.3	31.4	26.3
EV/EBIT(x)	78.7	63.7	52.7	42.1	34.8
EV/IC (x)	31.7	31.0	23.6	21.8	22.3
FCFF yield (%)	(0.4)	0.4	1.1	1.4	2.2
FCFE yield (%)	(0.5)	0.3	0.8	1.0	1.8
Dividend yield (%)	0.1	0.2	0.2	0.1	0.1
DuPont-RoE split					
Net profit margin (%)	22.1	21.1	21.2	22.4	24.4
Total asset turnover (x)	1.0	1.0	1.0	1.0	1.0
Assets/Equity (x)	0.9	0.9	0.9	0.9	0.9
RoE (%)	20.1	19.8	19.7	20.4	21.5
DuPont-RoIC					
NOPLAT margin (%)	22.7	22.2	22.4	23.5	24.3
IC turnover (x)	1.8	1.7	1.7	1.7	2.0
RoIC (%)	40.2	36.7	37.8	39.8	47.6
Operating metrics					
Core NWC days	(11.2)	(23.9)	3.9	2.5	1.3
Total NWC days	(11.2)	(23.9)	3.9	2.5	1.3
Fixed asset turnover	0.9	0.8	0.9	0.9	0.9
Opex-to-revenue (%)	47.7	47.5	47.0	45.2	45.2

Source: Company, Emkay Research


This report is intended for Team White Marque Solutions (team.emkay@whitemarqueresolutions)

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
22-Apr-26	1,041	1,300	Buy	Anshul Agrawal
07-Apr-26	929	1,300	Buy	Anshul Agrawal
20-Feb-26	1,009	1,300	Buy	Anshul Agrawal
14-Feb-26	988	1,300	Buy	Anshul Agrawal
11-Jan-26	993	1,225	Buy	Anshul Agrawal
24-Dec-25	1,030	1,225	Buy	Anshul Agrawal
05-Nov-25	1,025	1,225	Buy	Anshul Agrawal
08-Oct-25	991	1,225	Buy	Anshul Agrawal
30-Aug-25	1,008	1,225	Buy	Anshul Agrawal
29-Jul-25	1,120	1,225	Buy	Anshul Agrawal
09-Jul-25	1,019	1,150	Buy	Anshul Agrawal
20-Jun-25	930	1,150	Buy	Anshul Agrawal
13-May-25	970	1,150	Buy	Anshul Agrawal
10-Apr-25	971	1,150	Buy	Anshul Agrawal
03-Mar-25	933	1,200	Buy	Anshul Agrawal
12-Feb-25	1,026	1,200	Buy	Anshul Agrawal
07-Nov-24	1,025	1,100	Buy	Anshul Agrawal
07-Oct-24	983	1,025	Buy	Anshul Agrawal
29-Aug-24	892	1,025	Buy	Anshul Agrawal
06-Aug-24	809	850	Add	Anshul Agrawal

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Team White Marque Solutions (team.emkay@whitemarqueresolutions.com)

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of May 08, 2026
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report
Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of May 08, 2026
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the May 08, 2026
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for Team White Marque Solutions (team.emkay@whitemarqueresolutions.com)

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions.com)